3,4-dihydro-5-methyl-1(2h)-isoquinolinone has been researched along with nu 1025 in 4 studies
| Studies (3,4-dihydro-5-methyl-1(2h)-isoquinolinone) | Trials (3,4-dihydro-5-methyl-1(2h)-isoquinolinone) | Recent Studies (post-2010) (3,4-dihydro-5-methyl-1(2h)-isoquinolinone) | Studies (nu 1025) | Trials (nu 1025) | Recent Studies (post-2010) (nu 1025) |
|---|---|---|---|---|---|
| 16 | 0 | 2 | 39 | 0 | 17 |
| Protein | Taxonomy | 3,4-dihydro-5-methyl-1(2h)-isoquinolinone (IC50) | nu 1025 (IC50) |
|---|---|---|---|
| Chain A, Poly(adp-ribose) Polymerase | Gallus gallus (chicken) | 0.4 | |
| Chain A, Poly(adp-ribose) Polymerase | Gallus gallus (chicken) | 0.4 | |
| Chain A, Poly(adp-ribose) Polymerase | Gallus gallus (chicken) | 0.4 | |
| Poly [ADP-ribose] polymerase 1 | Mus musculus (house mouse) | 0.4 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bowman, K; Calvert, AH; Curtin, NJ; Golding, BT; Griffin, RJ; Newell, DR; Pemberton, LC; Srinivasan, S | 1 |
| Camaioni, E; Costantino, G; Macchiarulo, A; Pellicciari, R | 1 |
| Almassy, RJ; Boritzki, TJ; Calabrese, CR; Calvert, AH; Curtin, NJ; Ekkers, A; Golding, BT; Griffin, RJ; Hostomsky, Z; Kumpf, RA; Kyle, S; Li, J; Maegley, KA; Newell, DR; Thomas, HD; Tikhe, JG; Wang, LZ; Webber, SE; Yu, XH; Zhang, C | 1 |
| Jain, PG; Patel, BD | 1 |
1 review(s) available for 3,4-dihydro-5-methyl-1(2h)-isoquinolinone and nu 1025
| Article | Year |
|---|---|
Medicinal chemistry approaches of poly ADP-Ribose polymerase 1 (PARP1) inhibitors as anticancer agents - A recent update.
Topics: Animals; Antineoplastic Agents; Chemistry, Pharmaceutical; Humans; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Structure-Activity Relationship | 2019 |
3 other study(ies) available for 3,4-dihydro-5-methyl-1(2h)-isoquinolinone and nu 1025
| Article | Year |
|---|---|
Resistance-modifying agents. 5. Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase (PARP).
Topics: Alkylating Agents; Animals; Antineoplastic Agents; Cell Survival; Dacarbazine; DNA Repair; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Inhibitors; Gamma Rays; Leukemia L1210; Mice; Poly(ADP-ribose) Polymerase Inhibitors; Quinazolines; Structure-Activity Relationship; Tumor Cells, Cultured | 1998 |
Modeling of poly(ADP-ribose)polymerase (PARP) inhibitors. Docking of ligands and quantitative structure-activity relationship analysis.
Topics: Catalytic Domain; Crystallography, X-Ray; Enzyme Inhibitors; Ligands; Models, Molecular; Naphthalenes; Phenanthridines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Protein Binding; Quantitative Structure-Activity Relationship; Quinazolines | 2001 |
Design, synthesis, and evaluation of 3,4-dihydro-2H-[1,4]diazepino[6,7,1-hi]indol-1-ones as inhibitors of poly(ADP-ribose) polymerase.
Topics: Antineoplastic Agents; Azepines; Cell Line, Tumor; Cell Proliferation; Crystallography, X-Ray; Drug Design; Drug Resistance, Neoplasm; Drug Synergism; Humans; Indoles; Models, Molecular; Poly(ADP-ribose) Polymerase Inhibitors; Structure-Activity Relationship; Topoisomerase I Inhibitors | 2004 |